Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|NRAS Q61H PTEN over exp||rhabdomyosarcoma||sensitive||Ganitumab + Trametinib||Preclinical - Cell culture||Actionable||In a preclinical study, the addition of Ganitumab (AMG-479) sensitized a rhabdomyosarcoma cell line harboring NRAS Q61H and overexpressing PTEN to treatment with Mekinist (trametinib), resulting in reduced cell growth in culture (PMID: 36322002).||36322002|
|FLT3 exon 14 ins FLT3 D835X NRAS Q61H||acute myeloid leukemia||predicted - resistant||Gilteritinib||Case Reports/Case Series||Actionable||In a clinical study, a patient with acute myeloid leukemia harboring FLT3-ITD and a D835 mutation progressed on Xospata (gilteritinib) treatment and was found to have acquired NRAS Q61H (PMID: 31088841).||31088841|